Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.

Annals of surgical oncology - 1 Aug 2016

Chow Oliver S, Kuk Deborah, Keskin Metin, Smith J Joshua, Camacho Niedzica, Pelossof Raphael, Chen Chin-Tung, Chen Zhenbin, Avila Karin, Weiser Martin R, Berger Michael F, Patil Sujata, Bergsland Emily, Garcia-Aguilar Julio

Abstract excerpt

BACKGROUND: The response of rectal cancers to neoadjuvant chemoradiation (CRT) is variable, but tools to predict response remain lacking. We evaluated whether KRAS and TP53 mutations are associated with pathologic complete response (pCR) and lymph node metastasis after adjusting for neoadjuvant regimen. METHODS: Retrospective analysis of 229 pretreatment biopsies from patients with stage II/III rectal cancer was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Chemoradiotherapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphatic Metastasis

Share to Neoadjuvant Therapy

Share to Proto-Oncogene Proteins p21(ras)

Share to Rectal Neoplasms

Share to Survival Rate

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 27020587
DOI: 10.1245/s10434-016-5205-4
PMCID: PMC5047012

Genes

KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.PMID 27020587Read ↗

Influence of KRAS mutation subtypes on response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: meta-analysis.Semantic proximity Read ↗

KRAS mutation is predictive for poor prognosis in rectal cancer patients with neoadjuvant chemoradiotherapy: a systemic review and meta-analysis.Semantic proximity Read ↗

The effects of KRAS Mutations on the Prognosis of Rectal Cancer Following Neoadjuvant Chemoradiotherapy and Surgery.Semantic proximity Read ↗

KRAS mutation does not predict the efficacy of neo-adjuvant chemoradiotherapy in rectal cancer: a systematic review and meta-analysis.Semantic proximity Read ↗

The prognostic value of KRAS mutation in locally advanced rectal cancer.Semantic proximity Read ↗

Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma.Semantic proximity Read ↗

Impact of KRAS status on tumor response and survival after neoadjuvant treatment of locally advanced rectal cancer.Semantic proximity Read ↗

The prognostic value of KRAS mutation in locally advanced rectal cancer.Semantic proximity Read ↗

Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer.Semantic proximity Read ↗

A Genotype Signature for Predicting Pathologic Complete Response in Locally Advanced Rectal Cancer.Semantic proximity Read ↗

KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy.Semantic proximity Read ↗

Oncogene mutation profile predicts tumor regression and survival in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and radical surgery.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.